Danish drugmaker Lundbeck has beaten targets with a 30% rise in earnings for the second quarter, but its outlook for the year remains unchanged on expectations of a more challenging second half.

The company saw profit from operations of DKK 936 million, up 30% compared to the year ago period, as sales grew 7% to DKK 3.8 billion, with solid growth from most of its core products.

Revenue growth was driven by rocketing sales of Xenazine (tetrabenazine), for the treatment of chorea associated with Huntington's disease, and Azilect (rasagiline), for Parkinson’s disease, which were up at 70% at DKK 147 million and 42% at DKK 267 million, respectively (all at constant exchange rates).

Top seller Cipralex (escitalopram), for depression and anxiety, grew 5% to DKK 1.5 billion and Alzheimer’s disease drug Exiba (memantine) was up 9% at DKK 610 million. On the downside, turnover of Lexapro (escitalopram), which is sold in the US by Forest Laboratories, slid 13% to DKK 630 million, impacted by lower bulk deliveries compared to the same quarter last year, the firm explained.

But despite the substantial growth in earnings, the company has not lifted its full-year guidance of revenues of DKK 14.3-14.8 billion and EBIT of DKK 3.0-3.4 billion.

“The reason for not upgrading the guidance is that we'll see lower Lexapro sales, higher R&D costs, higher impact from European price reform and continued generic (competition) to our mature products in the US," Chief Financial Officer Anders Gotzsche told Reuters.

The group said it would provide longer-term guidance in the third quarter.